SOLICITATION NOTICE
Q -- Gene Expression Analysis Services
- Notice Date
- 4/2/2010
- Notice Type
- Presolicitation
- NAICS
- 541380
— Testing Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-100076-AV
- Archive Date
- 5/4/2010
- Point of Contact
- Ashley L. Virts,
- E-Mail Address
-
virtsa@mail.nih.gov
(virtsa@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Radiation Oncology Branch (ROB) plan to procure on a sole source basis with Genus Biosystems; 1808 Janke Drive; Unit M; Northbrook, Illinois 60062 for gene expression analysis services using Agilent whole genome arrays. The supplies are herein are being procured in accordance with the simplified acquisition procedures authorized by FAR Part 13.106- 1(b)(1). The North American Industry Classification System Code is 541380 and the business size standard is $12 million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. Period of Performance: Performance shall be for twelve months from date of award. The laboratory program in the ROB has a long-standing interest in radiation modifiers, particularly on aspects of the stress response. Over the last 4 years, the ROB has developed two themes that are now the focus of the program. This includes the concept of "fingerprinting" drugs using drug concentrations seen in the clinic and have demonstrated for COX-inhibitors (non-specific NSIADS, COX-2 specific and RNAi). There are substantial differences in gene expression among the high concentrations often used for mechanistic studies in the laboratory, the clinically achievable concentrations and RNA interference. Such discordance may account for the lack of translation of results from the lab to the clinic. The major emphasis builds on the concept of radiation as "focused biology" such that a radiation dose and schedule can be selected to induce a phenotypic change in the cancer cell, such that the cancer is now susceptible to molecular targeted therapy. Initial work was already completed in PC3 and DU145 cells using mRNA microarray analysis. The current objective is to find the inflection points of those differentially expressed genes using PC3 and DU 145 cell lines after the radiation. In order to be able to expand and complete the ongoing research, the micro-array analysis must be completed with previous experiments and analysis in order to ensure compatibility with previous results. The Contractor shall provide full service gene expression analysis using the Agilent Bioarray technology to provide amplification of the RNA, probe synthesis, hybridization to Agilent microarrays, scanning of the microarrays, and data analysis. The proposed Contractor offers several distinct advantages over other available services including high performance microarray metrics for sensitivity (< 1 copy cell, 95% within 1.5 fold), linear dynamic range (3.5 logs), reproducibility of 7-12% with extremely small amounts of data (50 picograms RNA) and comprehensive data analysis. The proposed analysis shall be conducted using GeneSpring software, which is one of the leading microarray data analysis packages available today. The software will provide unlimited data consulting time for the data analysis, in whichever combination is requested by the NCI. The analysis shall also include customized analysis and explanation of genomic data, data mining, integrated analysis of sequence and expression data, and cross-reference of public genomic databases. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on April 19, 2010. No electronic capability statements will be accepted (i.e. email or fax), an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Ashley Virts, Contract Specialist at virtsa@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-¬¬¬¬¬100076-AV on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-100076-AV/listing.html)
- Record
- SN02111980-W 20100404/100402235857-7c848b8d47fcacd462f64e09f4015912 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |